Q3 EPS Estimates for AngioDynamics Lowered by Zacks Research

AngioDynamics, Inc. (NASDAQ:ANGO) – Zacks Research lowered their Q3 2026 earnings estimates for shares of AngioDynamics in a report issued on Tuesday, March 25th. Zacks Research analyst D. Dey now anticipates that the medical instruments supplier will earn ($0.05) per share for the quarter, down from their prior forecast of ($0.04). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics’ Q4 2026 earnings at $0.00 EPS, FY2026 earnings at ($0.28) EPS and FY2027 earnings at ($0.18) EPS.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. AngioDynamics’s revenue for the quarter was down .1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.05) earnings per share.

Separately, HC Wainwright lifted their price target on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, January 10th.

AngioDynamics Stock Down 3.4 %

Shares of ANGO stock opened at $9.50 on Friday. The firm has a market cap of $384.43 million, a price-to-earnings ratio of -1.69 and a beta of 0.56. AngioDynamics has a 12 month low of $5.47 and a 12 month high of $13.50. The stock has a 50-day moving average price of $10.41 and a 200 day moving average price of $8.79.

Insider Buying and Selling

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares of the company’s stock, valued at $514,767.27. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.40% of the stock is owned by insiders.

Institutional Investors Weigh In On AngioDynamics

Large investors have recently bought and sold shares of the company. SBI Securities Co. Ltd. bought a new stake in shares of AngioDynamics in the 4th quarter valued at $28,000. BNP Paribas Financial Markets lifted its position in AngioDynamics by 110.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 159,391 shares of the medical instruments supplier’s stock valued at $1,240,000 after acquiring an additional 83,622 shares in the last quarter. State Street Corp lifted its holdings in shares of AngioDynamics by 2.7% in the third quarter. State Street Corp now owns 810,372 shares of the medical instruments supplier’s stock valued at $6,305,000 after purchasing an additional 21,218 shares in the last quarter. Barclays PLC grew its holdings in shares of AngioDynamics by 81.0% during the third quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier’s stock worth $651,000 after buying an additional 37,394 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of AngioDynamics by 28.7% in the third quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock valued at $4,304,000 after purchasing an additional 123,271 shares during the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.